A detailed history of Marshall Wace, LLP transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 79,888 shares of INMB stock, worth $365,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,888
Previous 115,916 31.08%
Holding current value
$365,088
Previous $1.02 Million 57.93%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.86 - $9.86 $175,096 - $355,236
-36,028 Reduced 31.08%
79,888 $430,000
Q2 2024

Aug 14, 2024

BUY
$7.15 - $11.84 $637,000 - $1.05 Million
89,091 Added 332.12%
115,916 $1.02 Million
Q1 2024

May 15, 2024

BUY
$10.53 - $14.01 $282,467 - $375,818
26,825 New
26,825 $315,000
Q2 2022

Aug 15, 2022

SELL
$5.48 - $8.97 $369,204 - $604,335
-67,373 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$6.42 - $11.39 $64,142 - $113,797
9,991 Added 17.41%
67,373 $568,000
Q4 2021

Feb 14, 2022

SELL
$9.97 - $20.38 $72,461 - $148,121
-7,268 Reduced 11.24%
57,382 $585,000
Q3 2021

Nov 15, 2021

BUY
$14.13 - $27.85 $913,504 - $1.8 Million
64,650 New
64,650 $1.26 Million

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $82M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.